NasdaqGM - Delayed Quote USD

Larimar Therapeutics, Inc. (LRMR)

6.44 +0.11 (+1.74%)
At close: April 26 at 4:00 PM EDT
6.57 +0.13 (+2.02%)
After hours: April 26 at 4:59 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for LRMR

Recent News: LRMR

View More

Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results
GuruFocus.com last month
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
GlobeNewswire last month
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
GlobeNewswire last month
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
GlobeNewswire last month
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
GlobeNewswire 2 months ago
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
GlobeNewswire 2 months ago
Larimar Therapeutics Announces Proposed Underwritten Public Offering

Larimar Therapeutics Announces Proposed Underwritten Public Offering
GlobeNewswire 2 months ago
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia
GlobeNewswire 2 months ago
With 45% ownership, Larimar Therapeutics, Inc. (NASDAQ:LRMR) has piqued the interest of hedge funds investors

With 45% ownership, Larimar Therapeutics, Inc. (NASDAQ:LRMR) has piqued the interest of hedge funds investors
Simply Wall St. 4 months ago
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
GlobeNewswire 5 months ago
Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference
GlobeNewswire 5 months ago
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
GlobeNewswire 6 months ago
View More

Related Tickers

AVTE Aerovate Therapeutics, Inc.
21.75
+0.83%
 
LXEO Lexeo Therapeutics, Inc.
12.50
+2.80%
 
LBPH Longboard Pharmaceuticals, Inc.
19.72
+2.44%
 
ENGN enGene Holdings Inc.
15.50
+5.30%
 
MORF Morphic Holding, Inc.
28.07
+0.32%
 
TYRA Tyra Biosciences, Inc.
15.67
+3.71%
 
CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%
 
NUVL Nuvalent, Inc.
66.86
+1.20%
 
EWTX Edgewise Therapeutics, Inc.
16.17
+1.44%
 
OLMA Olema Pharmaceuticals, Inc.
9.95
+1.22%